Differences in redox regulatory systems in human lung and liver tumors suggest different avenues for therapy

Cancers

Volumn 7, Issue 4, 2015, Pages 2262-2276

  Tobe, Ryuta ^a,e   Carlson, Bradley A ^a   Tsuji, Petra A ^b   Lee, Byeong Jae ^c   Gladyshev, Vadim N ^d   Hatfield, Dolph L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TOWSON UNIVERSITY   (United States)

^c Seoul National University   (South Korea)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e RITSUMEIKAN UNIVERSITY   (Japan)

Author keywords

Antioxidant systems; Glutathione; Glutathione peroxidase; Thioredoxin 1; Thioredoxin reductase 1

Indexed keywords

CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GAMMA GLUTAMYLTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE 1; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTAMATE CYSTEINE LIGASE; GLUTAREDOXIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE PEROXIDASE 2; GLUTATHIONE REDUCTASE; GLUTATHIONE S TRANSFERASE ALPHA 1; GLUTATHIONE S TRANSFERASE PI 1; GLUTATHIONE SYNTHASE; GLUTATHIONE TRANSFERASE ALPHA; PEROXIREDOXIN 1; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; THIOREDOXIN; THIOREDOXIN REDUCTASE 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CARCINOGENESIS; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; UPREGULATION;

EID: 84947087706     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7040889     Document Type: Article

References (76)

1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674. [CrossRef] [PubMed]
2. Chandel, N.S.; Tuveson, D.A. The promise and perils of antioxidants for cancer patients. N. Engl. J. Med. 2014, 371, 177-178. [PubMed]
3. Glasauer, A.; Chandel, N.S. Targeting antioxidants for cancer therapy. Biochem. Pharmacol. 2014, 92, 90-101. [CrossRef] [PubMed]
4. Gorrini, C.; Harris, I.S.; Mak, T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 2013, 12, 931-947. [CrossRef] [PubMed]
5. Gupta, S.C.; Hevia, D.; Patchva, S.; Park, B.; Koh, W.; Aggarwal, B.B. Upsides and downsides of reactive oxygen species for cancer: The roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid. Redox Signal. 2012, 16, 1295-1322. [CrossRef] [PubMed]
6. Kardeh, S.; Ashkani-Esfahani, S.; Alizadeh, A.M. Paradoxical action of reactive oxygen species in creation and therapy of cancer. Eur. J. Pharmacol. 2014, 735, 150-168. [CrossRef] [PubMed]
7. Pietraforte, D.; Malorni, W. Focusing at the double-edged sword of redox imbalance: Signals for cell survival or for cell death? Antioxid. Redox Signal. 2014, 21, 52-55. [CrossRef] [PubMed]
8. Sabharwal, S.S.; Schumacker, P.T. Mitochondrial ros in cancer: Initiators, amplifiers or an achilles' heel? Nat. Rev. Cancer 2014, 14, 709-721. [CrossRef] [PubMed]
9. Saeidnia, S.; Abdollahi, M. Antioxidants: Friends or foe in prevention or treatment of cancer: The debate of the century. Toxicol. Appl. Pharmacol. 2013, 271, 49-63. [CrossRef] [PubMed]
10. Dammeyer, P.; Arner, E.S. Human protein atlas of redox systems-What can be learnt? Biochim. Biophys. Acta 2011, 1810, 111-138. [CrossRef] [PubMed]
11. Godoy, J.R.; Funke, M.; Ackermann, W.; Haunhorst, P.; Oesteritz, S.; Capani, F.; Elsasser, H.P.; Lillig, C.H. Redox atlas of the mouse. Immunohistochemical detection of glutaredoxin-, peroxiredoxin-, and thioredoxin-family proteins in various tissues of the laboratory mouse. Biochim. Biophys. Acta 2011, 1810, 2-92. [CrossRef] [PubMed]
12. Harris, I.S.; Treloar, A.E.; Inoue, S.; Sasaki, M.; Gorrini, C.; Lee, K.C.; Yung, K.Y.; Brenner, D.; Knobbe-Thomsen, C.B.; Cox, M.A.; et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 2015, 27, 211-222. [CrossRef] [PubMed]
13. Hellfritsch, J.; Kirsch, J.; Schneider, M.; Fluege, T.;Wortmann, M.; Frijhoff, J.; Dagnell, M.; Fey, T.; Esposito, I.; Kolle, P.; et al. Knockout of mitochondrial thioredoxin reductase stabilizes prolyl hydroxylase 2 and inhibits tumor growth and tumor-derived angiogenesis. Antioxid. Redox Signal. 2015, 22, 938-950. [CrossRef] [PubMed]
14. Kiebala, M.; Skalska, J.; Casulo, C.; Brookes, P.S.; Peterson, D.R.; Hilchey, S.P.; Dai, Y.; Grant, S.; Maggirwar, S.B.; Bernstein, S.H. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant b cells: A novel synergistic therapeutic approach. Exp. Hematol. 2015, 43, 89-99. [CrossRef] [PubMed]
15. Kwee, J.K. A paradoxical chemoresistance and tumor suppressive role of antioxidant in solid cancer cells: A strange case of Dr. Jekyll and Mr. Hyde. Biomed. Res. Int. 2014, 2014, 209845. [CrossRef] [PubMed]
16. Lu, J.; Holmgren, A. The thioredoxin antioxidant system. Free Radic. Biol. Med. 2014, 66, 75-87. [CrossRef] [PubMed]
17. Mahmood, D.F.; Abderrazak, A.; el Hadri, K.; Simmet, T.; Rouis, M. The thioredoxin system as a therapeutic target in human health and disease. Antioxid. Redox Signal. 2013, 19, 1266-1303. [CrossRef] [PubMed]
18. Mandal, P.K.; Schneider, M.; Kolle, P.; Kuhlencordt, P.; Forster, H.; Beck, H.; Bornkamm, G.W.; Conrad, M. Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res. 2010, 70, 9505-9514. [CrossRef] [PubMed]
19. Peng, X.; Xu, J.; Arner, E.S. Thiophosphate and selenite conversely modulate cell death induced by glutathione depletion or cisplatin: Effects related to activity and sec contents of thioredoxin reductase. Biochem. J. 2012, 447, 167-174. [CrossRef] [PubMed]
20. Traverso, N.; Ricciarelli, R.; Nitti, M.; Marengo, B.; Furfaro, A.L.; Pronzato, M.A.; Marinari, U.M.; Domenicotti, C. Role of glutathione in cancer progression and chemoresistance. Oxid. Med. Cell. Longev. 2013, 2013, 972913. [CrossRef] [PubMed]
21. Sayin, V.I.; Ibrahim, M.X.; Larsson, E.; Nilsson, J.A.; Lindahl, P.; Bergo, M.O. Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med. 2014, 6, 221ra215. [CrossRef] [PubMed]
22. Zhao, F.; Yan, J.; Deng, S.; Lan, L.; He, F.; Kuang, B.; Zeng, H. A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines. Cancer Lett. 2006, 236, 46-53. [CrossRef] [PubMed]
23. Zhao, H.; Tang, J.; Xu, J.; Cao, L.; Jia, G.; Long, D.; Liu, G.; Chen, X.; Wang, K. Selenoprotein genes exhibit differential expression patterns between hepatoma HepG2 and normal hepatocytes LO2 cell lines. Biol. Trace Elem. Res. 2015, 167, 236-241. [CrossRef] [PubMed]
24. Novoselov, S.V.; Calvisi, D.F.; Labunskyy, V.M.; Factor, V.M.; Carlson, B.A.; Fomenko, D.E.; Moustafa, M.E.; Hatfield, D.L.; Gladyshev, V.N. Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene 2005, 24, 8003-8011. [CrossRef] [PubMed]
25. Kasaikina, M.V.; Turanov, A.A.; Avanesov, A.; Schweizer, U.; Seeher, S.; Bronson, R.T.; Novoselov, S.N.; Carlson, B.A.; Hatfield, D.L.; Gladyshev, V.N. Contrasting roles of dietary selenium and selenoproteins in chemically induced hepatocarcinogenesis. Carcinogenesis 2013, 34, 1089-1095. [CrossRef] [PubMed]
26. Brozmanova, J.; Manikova, D.; Vlckova, V.; Chovanec, M. Selenium: A double-edged sword for defense and offence in cancer. Arch. Toxicol. 2010, 84, 919-938. [CrossRef] [PubMed]
27. Hatfield, D.L.; Tsuji, P.A.; Carlson, B.A.; Gladyshev, V.N. Selenium and selenocysteine: Roles in cancer, health, and development. Trends Biochem. Sci. 2014, 39, 112-120. [CrossRef] [PubMed]
28. Steinbrenner, H.; Speckmann, B.; Sies, H. Toward understanding success and failures in the use of selenium for cancer prevention. Antioxid. Redox Signal. 2013, 19, 181-191. [CrossRef] [PubMed]
29. Vinceti, M.; Crespi, C.M.; Malagoli, C.; del Giovane, C.; Krogh, V. Friend or foe? The current epidemiologic evidence on selenium and human cancer risk. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2013, 31, 305-341. [CrossRef] [PubMed]
30. Carlson, B.A.; Yoo, M.H.; Tobe, R.; Mueller, C.; Naranjo-Suarez, S.; Hoffmann, V.J.; Gladyshev, V.N.; Hatfield, D.L. Thioredoxin reductase 1 protects against chemically induced hepatocarcinogenesis via control of cellular redox homeostasis. Carcinogenesis 2012, 33, 1806-1813. [CrossRef] [PubMed]
31. Cebula, M.; Schmidt, E.E.; Arner, E.S. TrxR1 as a potent regulator of the nrf2-keap1 response system. Antioxid. Redox Signal. 2015, 23, 823-853. [CrossRef] [PubMed]
32. Dai, B.; Yoo, S.Y.; Bartholomeusz, G.; Graham, R.A.; Majidi, M.; Yan, S.; Meng, J.; Ji, L.; Coombes, K.; Minna, J.D.; et al. Keap1-dependent synthetic lethality induced by akt and txnrd1 inhibitors in lung cancer. Cancer Res. 2013, 73, 5532-5543. [CrossRef] [PubMed]
33. Kansanen, E.; Kuosmanen, S.M.; Leinonen, H.; Levonen, A.L. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 2013, 1, 45-49. [CrossRef] [PubMed]
34. Lau, A.; Villeneuve, N.F.; Sun, Z.; Wong, P.K.; Zhang, D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res. 2008, 58, 262-270. [CrossRef] [PubMed]
35. Satoh, H.; Moriguchi, T.; Takai, J.; Ebina, M.; Yamamoto, M. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res. 2013, 73, 4158-4168. [CrossRef] [PubMed]
36. Yoo, M.H.; Xu, X.M.; Carlson, B.A.; Gladyshev, V.N.; Hatfield, D.L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem. 2006, 281, 13005-13008. [CrossRef] [PubMed]
37. Eriksson, S.E.; Prast-Nielsen, S.; Flaberg, E.; Szekely, L.; Arner, E.S. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic. Biol. Med. 2009, 47, 1661-1671. [CrossRef] [PubMed]
38. Suadicani, P.; Hein, H.O.; Gyntelberg, F. Serum selenium level and risk of lung cancer mortality: A 16-year follow-up of the copenhagen male study. Eur. Respir. J. 2012, 39, 1443-1448. [CrossRef] [PubMed]
39. Fritz, H.; Kennedy, D.; Fergusson, D.; Fernandes, R.; Cooley, K.; Seely, A.; Sagar, S.; Wong, R.; Seely, D. Selenium and lung cancer: A systematic review and meta analysis. PLoS ONE 2011, 6, e26259. [CrossRef] [PubMed]
40. Jaworska, K.; Gupta, S.; Durda, K.; Muszynska, M.; Sukiennicki, G.; Jaworowska, E.; Grodzki, T.; Sulikowski, M.; Waloszczyk, P.; Wojcik, J.; et al. A low selenium level is associated with lung and laryngeal cancers. PLoS ONE 2013, 8, e59051. [CrossRef] [PubMed]
41. Karp, D.D.; Lee, S.J.; Keller, S.M.; Wright, G.S.; Aisner, S.; Belinsky, S.A.; Johnson, D.H.; Johnston, M.R.; Goodman, G.; Clamon, G.; et al. Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J. Clin. Oncol. 2013, 31, 4179-4187. [CrossRef] [PubMed]
42. Huang, S.X.; Wu, F.X.; Luo, M.; Ma, L.; Gao, K.F.; Li, J.; Wu, W.J.; Huang, S.; Yang, Q.; Liu, K.; et al. The glutathione s-transferase p1 341c>t polymorphism and cancer risk: A meta-analysis of 28 case-control studies. PLoS ONE 2013, 8, e56722. [CrossRef] [PubMed]
43. Lu, S.C. Regulation of hepatic glutathione synthesis: Current concepts and controversies. FASEB J. 1999, 13, 1169-1183. [CrossRef] [PubMed]
44. Schnekenburger, M.; Karius, T.; Diederich, M. Regulation of epigenetic traits of the glutathione s-transferase p1 gene: From detoxification toward cancer prevention and diagnosis. Front. Pharmacol. 2014, 5. [CrossRef] [PubMed]
45. Singh, S. Cytoprotective and regulatory functions of glutathione s-transferases in cancer cell proliferation and cell death. Cancer Chemother. Pharmacol. 2015, 75. [CrossRef] [PubMed]
46. Balendiran, G.K.; Dabur, R.; Fraser, D. The role of glutathione in cancer. Cell Biochem. Funct. 2004, 22, 343-352. [CrossRef] [PubMed]
47. Arner, E.S.; Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 2000, 267, 6102-6109. [CrossRef] [PubMed]
48. Arner, E.S.J. Focus on mammalian thioredoxin reductases-Important selenoproteins with versatile functions. Biochim. Biophys. Acta Gen. Subj. 2009, 1790, 495-526. [CrossRef] [PubMed]
49. Rundlof, A.K.; Arner, E.S. Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid. Redox Signal. 2004, 6, 41-52. [CrossRef] [PubMed]
50. Rundlof, A.K.; Janard, M.; Miranda-Vizuete, A.; Arner, E.S. Evidence for intriguingly complex transcription of human thioredoxin reductase 1. Free Radic. Biol. Med. 2004, 36, 641-656. [CrossRef] [PubMed]
51. Arner, E.S.J.; Holmgren, A. The thioredoxin system in cancer. Semin. Cancer Biol. 2006, 16, 420-426. [CrossRef] [PubMed]
52. Biaglow, J.E.; Miller, R.A. The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy. Cancer Biol. Ther. 2005, 4, 6-13. [CrossRef] [PubMed]
53. Carlson, B.A. Dual functions of selenoproteins in cancer: Thioredoxin reductase. In Diversity of Selenium Functions in Health and Disease; Brigelius-Flohe, R., Sies, H., Eds.; CRC Press: Boca Raton, FL, USA, 2015; p. 430.
54. Gromer, S.; Urig, S.; Becker, K. The thioredoxin system-From science to clinic. Med. Res. Rev. 2004, 24, 40-89. [CrossRef] [PubMed]
55. Nguyen, P.; Awwad, R.T.; Smart, D.D.; Spitz, D.R.; Gius, D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. 2006, 236, 164-174. [CrossRef] [PubMed]
56. Itoh, K.; Mimura, J.; Yamamoto, M. Discovery of the negative regulator of Nrf2, Keap1: A historical overview. Antioxid. Redox Signal. 2010, 13, 1665-1678. [CrossRef] [PubMed]
57. Kensler, T.W.; Wakabayashi, N. Nrf2: Friend or foe for chemoprevention? Carcinogenesis 2010, 31, 90-99. [CrossRef] [PubMed]
58. Moon, E.J.; Giaccia, A. Dual roles of Nrf2 in tumor prevention and progression: Possible implications in cancer treatment. Free Radic. Biol. Med. 2015, 79, 292-299. [CrossRef] [PubMed]
59. Suvorova, E.S.; Lucas, O.; Weisend, C.M.; Rollins, M.F.; Merrill, G.F.; Capecchi, M.R.; Schmidt, E.E. Cytoprotective Nrf2 pathway is induced in chronically txnrd 1-deficient hepatocytes. PLoS ONE 2009, 4, e6158. [CrossRef] [PubMed]
60. Murakami, S.; Motohashi, H. Roles of Nrf2 in cell proliferation and differentiation. Free Radic. Biol. Med. 2015. [CrossRef] [PubMed]
61. Osburn, W.O.; Karim, B.; Dolan, P.M.; Liu, G.; Yamamoto, M.; Huso, D.L.; Kensler, T.W. Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int. J. Cancer 2007, 121, 1883-1891. [CrossRef] [PubMed]
62. Xu, C.; Huang, M.T.; Shen, G.; Yuan, X.; Lin, W.; Khor, T.O.; Conney, A.H.; Kong, A.N. Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in c57bl/6 mice by sulforaphane is mediated by nuclear factor e2-related factor 2. Cancer Res. 2006, 66, 8293-8296. [CrossRef] [PubMed]
63. Zhang, C.; Zhang, Z.; Zhu, Y.; Qin, S. Glucose-6-phosphate dehydrogenase: A biomarker and potential therapeutic target for cancer. Anticancer Agents Med. Chem. 2014, 14, 280-289. [CrossRef] [PubMed]
64. Jiang, P.; Du, W.; Wu, M. Regulation of the pentose phosphate pathway in cancer. Protein Cell 2014, 5, 592-602. [CrossRef] [PubMed]
65. Glorieux, C.; Zamocky, M.; Sandoval, J.M.; Verrax, J.; Calderon, P.B. Regulation of catalase expression in healthy and cancerous cells. Free Radic. Biol. Med. 2015, 87, 84-97. [CrossRef] [PubMed]
66. Papa, L.; Manfredi, G.; Germain, D. Sod1, an unexpected novel target for cancer therapy. Genes Cancer 2014, 5, 15-21. [PubMed]
67. Elchuri, S.; Oberley, T.D.; Qi, W.; Eisenstein, R.S.; Jackson Roberts, L.; van Remmen, H.; Epstein, C.J.; Huang, T.T. Cuznsod deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene 2005, 24, 367-380. [CrossRef] [PubMed]
68. Tsuji, P.A.; Carlson, B.A.; Yoo, M.H.; Naranjo-Suarez, S.; Xu, X.M.; He, Y.; Asaki, E.; Seifried, H.E.; Reinhold, W.C.; Davis, C.D.; et al. The 15kda selenoprotein and thioredoxin reductase 1 promote colon cancer by different pathways. PLoS ONE 2015, 10, e0124487. [CrossRef] [PubMed]
69. Friedmann Angeli, J.P.; Schneider, M.; Proneth, B.; Tyurina, Y.Y.; Tyurin, V.A.; Hammond, V.J.; Herbach, N.; Aichler, M.; Walch, A.; Eggenhofer, E.; et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 2014, 16, 1180-1191. [CrossRef] [PubMed]
70. Yang, W.S.; SriRamaratnam, R.; Welsch, M.E.; Shimada, K.; Skouta, R.; Viswanathan, V.S.; Cheah, J.H.; Clemons, P.A.; Shamji, A.F.; Clish, C.B.; et al. Regulation of ferroptotic cancer cell death by Gpx4. Cell 2014, 156, 317-331. [CrossRef] [PubMed]
71. Jackson, M.I.; Combs, G.F.J. Selenium as a cancer preventive agent. In Selenium: Its Molecular Biology and Role in Human Health, 3rd ed.; Hatfield, D.L., Berry, M.J., Gladyshev, V.N., Eds.; Springer Science + Business Media, LLC: New York, NY, USA, 2012.
72. Aldridge, G.M.; Podrebarac, D.M.; Greenough, W.T.; Weiler, I.J. The use of total protein stains as loading controls: An alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J. Neurosci. Methods 2008, 172, 250-254. [CrossRef] [PubMed]
73. Collins, M.A.; An, J.; Peller, D.; Bowser, R. Total protein is an effective loading control for cerebrospinal fluid western blots. J. Neurosci. Methods 2015, 251, 72-82. [CrossRef] [PubMed]
74. Eaton, S.L.; Roche, S.L.; Llavero Hurtado, M.; Oldknow, K.J.; Farquharson, C.; Gillingwater, T.H.; Wishart, T.M. Total protein analysis as a reliable loading control for quantitative fluorescent western blotting. PLoS ONE 2013, 8, e72457. [CrossRef] [PubMed]
75. Klein, D.; Kern, R.M.; Sokol, R.Z. A method for quantification and correction of proteins after transfer to immobilization membranes. Biochem. Mol. Biol. Int. 1995, 36, 59-66. [PubMed]
76. Welinder, C.; Ekblad, L. Coomassie staining as loading control in western blot analysis. J. Proteome Res. 2011, 10, 1416-1419. [CrossRef] [PubMed]